Skip to main content
. Author manuscript; available in PMC: 2018 Jun 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2017 Jun 1;75(2):232–240. doi: 10.1097/QAI.0000000000001361

Fig. 4. EGCG blocks macaque SEVI-mediated enhancement of SIV or SHIV infection of macaque PBMC.

Fig. 4

SIVmac239 (A), SIVmac251 (B) or SHIVSF162P3N (C) were pre-incubated with macaque SEVI (50 μg/mL) for 1 h. The mixture was then further incubated with or without the indicated concentrations of EGCG (10, 25, 50 μM) for 0.5 h prior to infection of macaque PBMC which were then washed once with PBS 3 h postinfection. Extracellular levels of SIV or SHIV RNA in culture supernatant and cell-associated viral RNA at the indicated time points were measured by qRT-PCR. Data were expressed as mean ± SD of three independent experiments (*P<0.05, **P<0.01, ***P<0.001, compared with macaque SEVI treatment only).